{"id":4111,"date":"2025-11-16T11:17:29","date_gmt":"2025-11-16T09:17:29","guid":{"rendered":"https:\/\/mypr.co.za\/mediainvite\/?p=641"},"modified":"2025-11-16T11:17:29","modified_gmt":"2025-11-16T09:17:29","slug":"digital-press-briefing-lenacapavir-delivery-and-the-america-first-global-health-strategy-delivering-on-the-u-s-governments-commitment-to-meaningfully-reduce-the-number-of-new-hiv-i","status":"publish","type":"post","link":"https:\/\/mypr.co.za\/mail\/digital-press-briefing-lenacapavir-delivery-and-the-america-first-global-health-strategy-delivering-on-the-u-s-governments-commitment-to-meaningfully-reduce-the-number-of-new-hiv-i\/","title":{"rendered":"Digital Press Briefing Lenacapavir Delivery and the America First Global Health Strategy \u2013 Delivering on the U.S. Government\u2019s commitment to meaningfully reduce the number of new HIV infections"},"content":{"rendered":"

EVENT<\/strong>:<\/strong><\/h3>\n

Please join us on\u00a0Tuesday, November 18, 2025<\/strong>, for a digital press briefing on an update to PEPFAR\u2019s commitment to reach up to 2 million people globally by 2028 with the breakthrough HIV drug Lenacapavir.\u00a0 The briefing will detail the first delivery of Lenacapavir in Eswatini and will include remarks by\u00a0State Department Senior Official Under Secretary for Foreign Assistance, Humanitarian Affairs, and Religious Freedom, Jeffrey Lewin; Charg\u00e9 d\u2019Affaires, ad interim, U.S. Embassy Eswatini, Marc Weinstock, Chairman of the Board of Directors and Chief Executive Officer of Gilead Sciences, Daniel O\u2019Day and Executive Director of the Global Fund, Peter Sands.\u00a0 \u00a0 \u00a0<\/strong><\/p>\n

On September 4, the U.S. government, in partnership with the Global Fund, committed to co-funding the purchase of the drug lenacapavir, a new and extremely effective HIV prevention injection that only has to be taken twice a year, for distribution to up to 2 million individuals in 8-12 high-burden HIV countries via the President\u2019s Emergency Plan for AIDS Relief (PEPFAR).\u00a0 Manufactured by Gilead Sciences, an American company, lenacapavir has the potential to significantly reduce new HIV infections, particularly among pregnant and breastfeeding women.<\/p>\n

Following the delivery of the first shipment of lenacapavir to Eswatini under this initiative, the call participants will discuss next steps toward fulfilling this important commitment, and the America First Global Health Strategy, which aims to make America safer, stronger, and more prosperous while saving millions of lives\u00a0around the world. After opening remarks, call participants will take questions from participating journalists.<\/p>\n

\n

DETAILS<\/strong>:<\/strong><\/h3>\n

Speakers:
\n<\/strong><\/p>\n